Abstract | PURPOSE: METHODS: RESULTS: At Days 7, 14, 30 and 42, emedastine was significantly better than levocabastine at controlling chemosis and eyelid swelling (p < 0.05). A statistical trend was seen at Day 3 (0.05 < p < 0.10). Results were clinically relevant at Days 30 and 42. Emedastine was also significantly better at reducing redness and itching at Days 7, 14, 30 and 42 (p < 0.05). CONCLUSION:
|
Authors | A Secchi, A Leonardi, M Discepola, J Deschenes, M B Abelson |
Journal | Acta ophthalmologica Scandinavica. Supplement
(Acta Ophthalmol Scand Suppl)
Issue 230
Pg. 48-51
( 2000)
ISSN: 1395-3931 [Print] Denmark |
PMID | 11057351
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Benzimidazoles
- Histamine H1 Antagonists
- Ophthalmic Solutions
- Piperidines
- emedastine
- levocabastine
|
Topics |
- Adolescent
- Adult
- Aged
- Benzimidazoles
(administration & dosage, adverse effects, therapeutic use)
- Child
- Child, Preschool
- Conjunctiva
(drug effects)
- Conjunctivitis, Allergic
(drug therapy, pathology)
- Double-Blind Method
- Edema
(drug therapy, pathology)
- Eyelid Diseases
(drug therapy, pathology)
- Female
- Histamine H1 Antagonists
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Ophthalmic Solutions
- Piperidines
(administration & dosage, adverse effects, therapeutic use)
- Safety
- Seasons
- Treatment Outcome
|